IDEAYA Biosciences Secures $150M Credit Facility
Ticker: IDYA · Form: 8-K · Filed: Jul 31, 2024 · CIK: 1676725
| Field | Detail |
|---|---|
| Company | Ideaya Biosciences, Inc. (IDYA) |
| Form Type | 8-K |
| Filed Date | Jul 31, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $6.5 million, $400.0 m, $100.0 million |
| Sentiment | bullish |
Sentiment: bullish
Topics: financing, debt, credit-facility
TL;DR
IDEAYA just locked down a $150M credit line, $100M drawn now, to fund their cancer drug pipeline.
AI Summary
On July 30, 2024, IDEAYA Biosciences, Inc. entered into a material definitive agreement, specifically a Second Amended and Restated Credit Agreement. This agreement involves a new term loan facility of $150 million, with an initial draw of $100 million. The agreement also includes an option to increase the term loan facility by an additional $50 million.
Why It Matters
This significant financing provides IDEAYA with substantial capital to advance its pipeline of precision oncology therapies, potentially accelerating drug development and market entry.
Risk Assessment
Risk Level: medium — While the financing provides capital, the success of the company is still dependent on the clinical and commercial success of its drug candidates.
Key Numbers
- $150.0M — Credit Facility Size (Total potential financing available under the new agreement.)
- $100.0M — Initial Draw (Amount drawn immediately upon closing the credit agreement.)
Key Players & Entities
- IDEAYA Biosciences, Inc. (company) — Registrant
- Second Amended and Restated Credit Agreement (agreement) — Material Definitive Agreement
- $150 million (dollar_amount) — Total term loan facility
- $100 million (dollar_amount) — Initial draw on term loan facility
- $50 million (dollar_amount) — Option to increase term loan facility
- July 30, 2024 (date) — Date of Report
FAQ
What is the primary purpose of the new credit agreement?
The credit agreement provides IDEAYA Biosciences with a new term loan facility to support its operations and advance its pipeline of precision oncology therapies.
What is the total amount of the term loan facility?
The Second Amended and Restated Credit Agreement establishes a term loan facility of $150 million.
How much was initially drawn from the term loan facility?
IDEAYA Biosciences initially drew $100 million from the term loan facility.
Does the agreement allow for additional funding?
Yes, the agreement includes an option for IDEAYA Biosciences to increase the term loan facility by an additional $50 million.
When was this material definitive agreement entered into?
The agreement was entered into on July 30, 2024.
Filing Stats: 829 words · 3 min read · ~3 pages · Grade level 12.9 · Accepted 2024-07-31 06:03:19
Key Financial Figures
- $0.0001 — e on which registered Common Stock, $0.0001 par value per share IDYA The Nasdaq
- $6.5 million — Option, an exercise fee totaling up to $6.5 million. The Option is exercisable by the Compa
- $400.0 m — ilestone payments equal an aggregate of $400.0 million, including development and regula
- $100.0 million — regulatory milestone payments of up to $100.0 million. The Company's royalty obligations cont
Filing Documents
- idya-20240730.htm (8-K) — 60KB
- idya-ex99_1.htm (EX-99.1) — 26KB
- img107722786_0.jpg (GRAPHIC) — 3KB
- 0000950170-24-088200.txt ( ) — 215KB
- idya-20240730.xsd (EX-101.SCH) — 30KB
- idya-20240730_htm.xml (XML) — 5KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On July 31, 2024, IDEAYA Biosciences, Inc. (the "Company") announced that it had entered into an Option and License Agreement (the "Agreement"), dated July 30, 2024 (the "Effective Date"), with Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen"), pursuant to which Biocytogen granted to the Company an option for an exclusive worldwide license to develop and commercialize products in connection with a potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate program (the "Option"). Pursuant to the Agreement, the Company will pay Biocytogen an upfront fee and, upon the Company's potential exercise of the Option, an exercise fee totaling up to $6.5 million. The Option is exercisable by the Company within a specified time period after the Company obtains all data and results from certain non-GLP toxicology studies specified in the Agreement, which the Company will conduct at its own cost. The Agreement will continue in effect on a product-by-product and country-by-country basis until the expiration of the obligation to make payments under the Agreement with respect to such product in each country, unless earlier terminated by either party pursuant to its terms. Either
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated July 31, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEAYA BIOSCIENCES, INC. Date: July 31, 2024 By: /s/ Yujiro Hata Yujiro Hata President and Chief Executive Officer